Novel combined single dose anti-hepatitis C therapy: a pilot study

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Hepatitis C virus (HCV) treatments have advanced, yet challenges remain in efficacy and tolerability across genotypes.
• Novel therapeutic strategies are needed to target the HCV infectious cycle comprehensively and combat diverse HCV genotypes.

Purpose of the Study:

• To evaluate the efficacy and safety of Catvira, a novel formulation of epigallocatechingallate (EGCG) plus sofosbuvir plus ribavirin.
• To compare Catvira with sofosbuvir plus ribavirin in patients with chronic Hepatitis C virus genotype 4 infection.

Main Methods:

• A randomized open-label study (NCT02483156) involving 80 treatment-naïve and treatment-experienced patients with HCV genotype 4.
• Participants received daily fixed doses of either Catvira or sofosbuvir plus ribavirin for 12 or 24 weeks.
• Efficacy was assessed by viral load decline and sustained virologic response (SVR12); safety was evaluated by monitoring hemoglobin levels.

Main Results:

• Both Catvira and sofosbuvir plus ribavirin achieved significant viral load reduction (p < 0.001).
• Catvira demonstrated a more rapid viral load decline, with 90% of patients achieving SVR12 after 12 weeks of treatment.
• Catvira did not affect hemoglobin levels, whereas sofosbuvir plus ribavirin showed a significant decline after 24 weeks (p < 0.05).

Conclusions:

• Catvira is a safe, effective, and well-tolerated treatment for patients with HCV genotype 4, regardless of prior treatment history.
• The 12-week Catvira regimen offers a promising therapeutic option with a rapid response and favorable safety profile.
• Catvira represents a significant advancement in HCV treatment, particularly for its improved tolerability concerning hematological parameters.